Characterization of glycan substrates accumulating in GM1 Gangliosidosis
| العنوان: | Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
|---|---|
| المؤلفون: | Brett E. Crawford, Adam Harris, Jeremy L. Van Vleet, Roberto Giugliani, Sanjay Chandriani, Roger Lawrence, Gouri Yogalingam, Linley Mangini, Nathan T. Martin, Wyatt T. Clark, Alessandra d'Azzo, Jonathan H. LeBowitz |
| المصدر: | Repositório Institucional da UFRGS Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS Molecular Genetics and Metabolism Reports Molecular Genetics and Metabolism Reports, Vol 21, Iss, Pp-(2019) |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Glycoconjugate, MPS, mucopolysaccharidosis, GRIL-LC/MS, glycan reductive isotope labeling liquid chromatography mass spectrometry, BMP, Bis(monoacylglycero) phosphate, TIC, total ion current, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, KS, keratan sulfate, Disease biomarkers, Beta-galactosidase, Hex, hexose, lcsh:QH301-705.5, chemistry.chemical_classification, lcsh:R5-920, 0303 health sciences, Gangliosidose GM1, biology, 030305 genetics & heredity, GlcNAc, N-acetylglucosamine, GLB1, Biochemistry, HexNAc, N-acetylhexosamine, lcsh:Medicine (General), Research Paper, Glycan, GM1 gangliosidosis, GLB1, β-galactosidase, A2G2, Oxford glycan naming designation for NA2 glycan, 03 medical and health sciences, Glycoanalysis, Glycolipid, dp, degree of polymerization, Genetics, Glycan metabolites, Molecular Biology, NRE, non-reducing end, m/z, mass over charge, Ganglioside, Man, mannose, carbohydrates (lipids), Gal, galactose, Enzyme, Biomarcadores, lcsh:Biology (General), chemistry, Galactose, biology.protein, XIC, extracted ion current, 030217 neurology & neurosurgery |
| الوصف: | Introduction: GM1 gangliosidosis is a rare autosomal recessive genetic disorder caused by the disruption of the GLB1 gene that encodes β-galactosidase, a lysosomal hydrolase that removes β-linked galactose from the non-reducing end of glycans. Deficiency of this catabolic enzyme leads to the lysosomal accumulation of GM1 and its asialo derivative GA1 in β-galactosidase deficient patients and animal models. In addition to GM1 and GA1, there are other glycoconjugates that contain β-linked galactose whose metabolites are substrates for β-galactosidase. For example, a number of N-linked glycan structures that have galactose at their non-reducing end have been shown to accumulate in GM1 gangliosidosis patient tissues and biological fluids. Objective: In this study, we attempt to fully characterize the broad array of GLB1 substrates that require GLB1 for their lysosomal turnover. Results: Using tandem mass spectrometry and glycan reductive isotope labeling with data-dependent mass spectrometry, we have confirmed the accumulation of glycolipids (GM1 and GA1) and N-linked glycans with terminal beta-linked galactose. We have also discovered a novel set of core 1 and 2 O-linked glycan metabolites, many of which are part of structurally-related isobaric series that accumulate in disease. In the brain of GLB1 null mice, the levels of these glycan metabolites increased along with those of both GM1 and GA1 as a function of age. In addition to brain tissue, we found elevated levels of both N-linked and O-linked glycan metabolites in a number of peripheral tissues and in urine. Both brain and urine samples from human GM1 gangliosidosis patients exhibited large increases in steady state levels for the same glycan metabolites, demonstrating their correlation with this disease in humans as well. Conclusions: Our studies illustrate that GLB1 deficiency is not purely a ganglioside accumulation disorder, but instead a broad oligosaccharidosis that include representatives of many β-linked galactose containing glycans and glycoconjugates including glycolipids, N-linked glycans, and various O-linked glycans. Accounting for all β-galactosidase substrates that accumulate when this enzyme is deficient increases our understanding of this severe disorder by identifying metabolites that may drive certain aspects of the disease and may also serve as informative disease biomarkers to fully evaluate the efficacy of future therapies. Keywords: GM1 gangliosidosis, GLB1, Beta-galactosidase, Glycan metabolites, Disease biomarkers, Glycoanalysis |
| وصف الملف: | application/pdf |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fad1e65eec41e62a514a14a12ceec192Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fad1e65eec41e62a514a14a12ceec192 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |